TickerFacts.

Adaptin Bio, Inc. (APTN): Cash & Equivalents

Annual figures by period end, from SEC filings.

$459.2K
As of 2025-12-31
$670.5K
As of 2026-06-30
n/m
3-year compound annual growth
2022-12-31: $5002023-12-31: $3802024-12-31: $34.1K2025-12-31: $459.2K$459.2K
2022-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$459.2Kn/m2026-04-01, Balance as of period end
2024-12-31$34.1Kn/m2026-04-01, Balance as of period end
2023-12-31$380-24.0%2024-04-01, Balance as of period end
2022-12-31$500n/a2024-04-01, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Adaptin Bio, Inc. (APTN)2025-12-31$459.2Kn/m
Brainstorm Cell Therapeutics Inc. (BCLI)2025-12-31$29.0K-84.5%
Abpro Holdings, Inc. (ABPO)2024-12-31$2.85M+294.2%
Estrella Immunopharma, Inc. (ESLA)2025-12-31$1.38M+51.0%
BioCardia, Inc. (BCDA)2025-12-31$2.50M+5.3%
Tevogen Inc. (TVGN)2025-12-31$0n/a
Eloxx Pharmaceuticals, Inc. (ELOX)2025-12-31$4.79Mn/m
AIM ImmunoTech Inc. (AIM)2025-12-31$2.98M+75.5%
Exozymes Inc. (EXOZ)2025-12-31$3.04M-68.7%

Compare APTN, BCLI, ABPO, ESLA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗